Molecular targeting therapies for neuroblastoma: Progress and challenges is a research paper published in Medicinal Research Reviews (2020). On theSindex it has a DataRank of 0. It has been cited 395 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
American Cancer Society
Grant: RSG‐15‐009‐01‐CDD
National Science Foundation
Grant: 1R01CA241600‐01
National Science Foundation
Grant: 1R01DK115445‐01A1
National Science Foundation
Grant: R01CA186662
National Science Foundation
Grant: R01CA214019
National Science Foundation
Grant: U24CA228550
Cancer Prevention and Research Institute of Texas
Grant: RR150104
Cancer Prevention and Research Institute of Texas
Grant: RR1550088
NCI NIH HHS
Grant: R01 CA241600
NIDDK NIH HHS
Grant: R01 DK115445
National Institutes of Health
Grant: 5R01CA214019-03
Novel NFAT1-MDM2 inhibitor for Breast Cancer Therapy
National Institutes of Health
Grant: 7R01CA186662-05
Novel Small Molecule MDM2 Inhibitors for Pancreatic Cancer Therapy
National Institutes of Health
Grant: 5R01CA241600-05
Clonal Reconstruction and Targeting of the Correa Sequence
National Institutes of Health
Grant: 5R01DK115445-02
Pathogenic Heterogeneity in Mucosal Stem Cells in Pediatric Crohn's Disease
National Institutes of Health
Grant: 5U24CA228550-05
Patient-Matched Stem Cells of the Barrett's-Dysplasia-Adenocarcinoma Sequence
FWCI
15.91
Citation Percentile
1.0%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals
Additional file 1 of MYCN protein stability is a better prognostic indicator in neuroblastoma
Additional file 1 of MYCN protein stability is a better prognostic indicator in neuroblastoma
Additional file 2 of MYCN protein stability is a better prognostic indicator in neuroblastoma
Additional file 2 of MYCN protein stability is a better prognostic indicator in neuroblastoma
Additional file 3 of MYCN protein stability is a better prognostic indicator in neuroblastoma
Additional file 3 of MYCN protein stability is a better prognostic indicator in neuroblastoma
Additional file 4 of MYCN protein stability is a better prognostic indicator in neuroblastoma
Additional file 4 of MYCN protein stability is a better prognostic indicator in neuroblastoma
Additional file 5 of MYCN protein stability is a better prognostic indicator in neuroblastoma
Additional file 5 of MYCN protein stability is a better prognostic indicator in neuroblastoma
Additional file 1 of SMAD9-MYCN positive feedback loop represents a unique dependency for MYCN-amplified neuroblastoma
Additional file 1 of SMAD9-MYCN positive feedback loop represents a unique dependency for MYCN-amplified neuroblastoma
Additional file 1 of LncRNA AC142119.1 facilitates the progression of neuroblastoma by epigenetically initiating the transcription of MYCN
Additional file 1 of LncRNA AC142119.1 facilitates the progression of neuroblastoma by epigenetically initiating the transcription of MYCN
Additional file 2 of Identification of RECK as a protective prognostic indicator and a tumor suppressor through regulation of the ERK/MAPK signaling pathway in gastric cancer
Additional file 2 of Identification of RECK as a protective prognostic indicator and a tumor suppressor through regulation of the ERK/MAPK signaling pathway in gastric cancer
Additional file 1 of Clinical characteristics and prognoses in pediatric neuroblastoma with bone or liver metastasis: data from the SEER 2010–2019
Additional file 1 of Clinical characteristics and prognoses in pediatric neuroblastoma with bone or liver metastasis: data from the SEER 2010–2019
Additional file 2 of Clinical characteristics and prognoses in pediatric neuroblastoma with bone or liver metastasis: data from the SEER 2010–2019
Additional file 2 of Clinical characteristics and prognoses in pediatric neuroblastoma with bone or liver metastasis: data from the SEER 2010–2019